Whitney K. Stewart

Preclinical and Clinical Resistance Mechanisms To The Investigational Selective FLT3 Inhibitor PLX3397 In FLT3-ITD+ Acute Myeloid Leukemia (AML)

A. Kasarskis, R. Sebra, A. Bashir, 2013 .

Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD.

Catherine C. Smith, E. A. Lasater, N. Shah, 2013, Blood.

Crenolanib is a selective type I pan-FLT3 inhibitor

J. Kuriyan, M. Carroll, S. Kogan, 2014, Proceedings of the National Academy of Sciences.

Crenolanib (CP-868,596) Is a Potent and Selective Type I FLT3 Inhibitor That Retains Activity Against AC220 Resistance-Causing FLT3 Kinase Domain Mutants

M. Carroll, S. Kogan, Catherine C. Smith, 2012 .

Constitutively Activating Mutations At the FLT3 Activation Loop Residue D835 Are Associated with Clinical Resistance to AC220

A. Kasarskis, K. Travers, J. Radich, 2012 .